BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jayasinghe S, Chiu C, Quinn H, Menzies R, Gilmour R, McIntyre P. Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational Study. Clin Infect Dis 2018;67:367-74. [PMID: 29471432 DOI: 10.1093/cid/ciy129] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Whitney CG. Examining Duration of Protection: Should a Booster Dose Be Part of All Infant Pneumococcal Conjugate Vaccine Programs? Clinical Infectious Diseases 2018;67:375-7. [DOI: 10.1093/cid/ciy135] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
2 Lagousi T, Papadatou I, Strempas P, Chatzikalil E, Spoulou V. Pneumococcal Immunization Strategies for High-Risk Pediatric Populations Worldwide: One Size Does Not Fit All. Vaccines (Basel) 2021;9:1390. [PMID: 34960136 DOI: 10.3390/vaccines9121390] [Reference Citation Analysis]
3 Chan J, Gidding HF, Blyth CC, Fathima P, Jayasinghe S, McIntyre PB, Moore HC, Mulholland K, Nguyen CD, Andrews R, Russell FM. Levels of pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: An observational study. PLoS Med 2021;18:e1003733. [PMID: 34343186 DOI: 10.1371/journal.pmed.1003733] [Reference Citation Analysis]
4 Chua H, Feng S, Lewnard JA, Sullivan SG, Blyth CC, Lipsitch M, Cowling BJ. The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology. Epidemiology 2020;31:43-64. [PMID: 31609860 DOI: 10.1097/EDE.0000000000001116] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 19.0] [Reference Citation Analysis]
5 Gidding HF, McCallum L, Fathima P, Moore HC, Snelling TL, Blyth CC, Jayasinghe S, Giele C, de Klerk N, Andrews RM, McIntyre PB; ACIR linkage Investigator Team. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia. Vaccine 2018;36:2650-6. [PMID: 29627233 DOI: 10.1016/j.vaccine.2018.03.058] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
6 Kitano T, Aoki H. The incremental burden of invasive pneumococcal disease associated with a decline in childhood vaccination using a dynamic transmission model in Japan: A secondary impact of COVID-19. Comput Biol Med 2021;133:104429. [PMID: 33930765 DOI: 10.1016/j.compbiomed.2021.104429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Treskova M, Scholz SM, Kuhlmann A. Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions. PharmacoEconomics 2019;37:1093-127. [DOI: 10.1007/s40273-019-00805-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Madhi SA, Mutsaerts EA, Izu A, Boyce W, Bhikha S, Ikulinda BT, Jose L, Koen A, Nana AJ, Moultrie A, Roalfe L, Hunt A, Goldblatt D, Cutland CL, Dorfman JR. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial. Lancet Infect Dis 2020;20:1426-36. [PMID: 32857992 DOI: 10.1016/S1473-3099(20)30289-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ricketson LJ, Bettinger JA, Sadarangani M, Halperin SA, Kellner JD. Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.03.048] [Reference Citation Analysis]
10 Ladhani SN, Ramsay ME. Smart Scheduling: Optimizing National Immunization Programs to Achieve Maximum Impact. Clin Infect Dis 2020;70:684-6. [PMID: 31209467 DOI: 10.1093/cid/ciz500] [Reference Citation Analysis]
11 Mills RO, Abdullah MR, Akwetey SA, Sappor DC, Cole I, Baffuor-Asare M, Bolivar JA, Gámez G, van der Linden MPG, Hammerschmidt S. Post-Vaccination Streptococcus pneumoniae Carriage and Virulence Gene Distribution among Children Less Than Five Years of Age, Cape Coast, Ghana. Microorganisms 2020;8:E1987. [PMID: 33322236 DOI: 10.3390/microorganisms8121987] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Wiese AD, Grijalva CG. To Boost or Not to Boost? Lessons from the Australian Pneumococcal Conjugate Vaccination Program. Clin Infect Dis 2020;70:2616-8. [PMID: 31388668 DOI: 10.1093/cid/ciz735] [Reference Citation Analysis]
13 Congdon M, Hong H, Young RR, Cunningham CK, Enane LA, Arscott-Mills T, Banda FM, Chise M, Motlhatlhedi K, Feemster K, Patel SM, Boiditswe S, Leburu T, Shah SS, Steenhoff AP, Kelly MS. Effect of Haemophilus influenzae Type b and 13-Valent Pneumococcal Conjugate Vaccines on Childhood Pneumonia Hospitalizations and Deaths in Botswana. Clin Infect Dis 2021;73:e410-6. [PMID: 32634831 DOI: 10.1093/cid/ciaa919] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Izurieta P, Nieto Guevara J. Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease. Hum Vaccin Immunother 2021;:1-8. [PMID: 33605846 DOI: 10.1080/21645515.2021.1872341] [Reference Citation Analysis]
15 Malchrzak W, Mastalerz-Migas A. Epidemiologic Benefits of Pneumococcal Vaccine Introduction into Preventive Vaccination Programs. Adv Exp Med Biol 2021;1324:11-9. [PMID: 33136238 DOI: 10.1007/5584_2020_589] [Reference Citation Analysis]
16 Valenciano SJ, Moiane B, Lessa FC, Chaúque A, Massora S, Pimenta FC, Mucavele H, Verani JR, da Gloria Carvalho M, Whitney CG, Tembe N, Sigaúque B. Effect of 10-Valent Pneumococcal Conjugate Vaccine on Streptococcus pneumoniae Nasopharyngeal Carriage Among Children Less Than 5 Years Old: 3 Years Post-10-Valent Pneumococcal Conjugate Vaccine Introduction in Mozambique. J Pediatric Infect Dis Soc 2021;10:448-56. [PMID: 33245124 DOI: 10.1093/jpids/piaa132] [Reference Citation Analysis]
17 Dunn MG, Lessa FC, Sánchez J, Cordero R, Feris-Iglesias J, Cedano D, Carvalho MDG, Fernández J, Feemster KA. Impact of 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage Rates of Streptococcus pneumoniae in a Rural Community in the Dominican Republic. J Infect Dis 2021;224:S237-47. [PMID: 34469551 DOI: 10.1093/infdis/jiab172] [Reference Citation Analysis]
18 Janapatla RP, Hsu MH, Chen CL, Wei SH, Yu MJ, Su LH, Lin TY, Chiu CH. Persistence of immunity in children immunised with 13-valent pneumococcal conjugate vaccine and impact on nasopharyngeal carriage: a cross-sectional study. Thorax 2020;75:689-92. [PMID: 32444435 DOI: 10.1136/thoraxjnl-2019-213878] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Mungall BA, Hoet B, Nieto Guevara J, Soumahoro L. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. Expert Rev Vaccines 2021. [PMID: 34882050 DOI: 10.1080/14760584.2022.2012455] [Reference Citation Analysis]
20 Chan J, Nguyen CD, Dunne EM, Kim Mulholland E, Mungun T, Pomat WS, Rafai E, Satzke C, Weinberger DM, Russell FM. Using pneumococcal carriage studies to monitor vaccine impact in low- and middle-income countries. Vaccine 2019;37:6299-309. [PMID: 31500968 DOI: 10.1016/j.vaccine.2019.08.073] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
21 Hernstadt H, Cheung A, Hurem D, Vasilunas N, Phuong LK, Quinn P, Agrawal R, Daley AJ, Cole T, Gwee A. Changing Epidemiology and Predisposing Factors for Invasive Pneumococcal Disease at Two Australian Tertiary Hospitals. Pediatr Infect Dis J 2020;39:1-6. [PMID: 31815835 DOI: 10.1097/INF.0000000000002489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 Zimmermann P, Perrett KP, Berbers G, Curtis N. Persistence of pneumococcal antibodies after primary immunisation with a polysaccharide-protein conjugate vaccine. Arch Dis Child 2019;104:680-4. [PMID: 30796020 DOI: 10.1136/archdischild-2018-316254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Maguire JE, Beard F, Méder K, Dey A, Macartney K, McIntyre P. Australian vaccine preventable disease epidemiological review series: invasive Haemophilus influenzae type b disease, 2000-2017. Commun Dis Intell (2018) 2020;44. [PMID: 32114977 DOI: 10.33321/cdi.2020.44.11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Hammitt LL, Etyang AO, Morpeth SC, Ojal J, Mutuku A, Mturi N, Moisi JC, Adetifa IM, Karani A, Akech DO, Otiende M, Bwanaali T, Wafula J, Mataza C, Mumbo E, Tabu C, Knoll MD, Bauni E, Marsh K, Williams TN, Kamau T, Sharif SK, Levine OS, Scott JAG. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet 2019;393:2146-54. [PMID: 31000194 DOI: 10.1016/S0140-6736(18)33005-8] [Cited by in Crossref: 56] [Cited by in F6Publishing: 28] [Article Influence: 18.7] [Reference Citation Analysis]
25 Kaboré L, Adebanjo T, Njanpop-Lafourcade BM, Ouangraoua S, Tarbangdo FT, Meda B, Velusamy S, Bicaba B, Aké F, McGee L, Yaro S, Betsem E, Gervaix A, Gessner BD, Whitney CG, Moïsi JC, Van Beneden CA. Pneumococcal Carriage in Burkina Faso After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Results From 2 Cross-sectional Population-Based Surveys. J Infect Dis 2021;224:S258-66. [PMID: 34469552 DOI: 10.1093/infdis/jiab037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]